TY - JOUR
T1 - Raman spectroscopy, a potential tool in diagnosis and prognosis of castration-resistant prostate cancer
AU - Wang, Lei
AU - He, Dalin
AU - Zeng, Jin
AU - Guan, Zhenfeng
AU - Dang, Qiang
AU - Wang, Xinyang
AU - Wang, Jun
AU - Huang, Liqing
AU - Cao, Peilong
AU - Zhang, Guanjun
AU - Hsieh, Jertong
AU - Fan, Jinhai
N1 - Funding Information:
The authors thank Professor Leland W.K. Chung at Cedars-Sinai Medical Center, Los Angeles, USA, for provision of C4-2 cells, Dr. Quan-li Wang at Department of Epidemiology and Health Statistics, Xi’an Jiaotong University College of Medicine, China, for the help with statistical analysis, Professor Victor K. Lin at Department of Urology, University of Texas Southwestern Medical Center, USA, for his excellent job critically revising this manuscript. Funding: National Natural Science Foundation of China (No. 30701009) and National Basic Research Program of China (973 Program, No. 2009CB526408).
PY - 2013/8
Y1 - 2013/8
N2 - Purpose: We evaluated the feasibility of Raman spectroscopy (RS) in diagnosis and prognosis of castration-resistant prostate cancer (CRPC) in patients with prostate cancer (PC). Materials and methods: Raman spectra are detected from PC cell lines (LNCaP and C4-2) and tissues using a Labram HR 800 RS. Then, principal component analysis (PCA) and support vector machine (SVM) are applied for prediction. A leave-one-out cross-validation is used to train and test the SVM. Results: There are 50 qualified patients, including 33 with androgendependent prostate cancer (ADPC) and 17 with CRPC. The spectral changes at 1126, 1170, 1315 to 1338, and 1447 cm-1 between CRPC and ADPC are detected in both cells and tissues models, which are assigned to specific amino acids and DNA. PCA/SVM algorithm provided a sensitivity of 88.2% and a specificity of 87.9% for diagnosing CRPC tissues. Furthermore, 14 patients with ADPC progressed to CRPC within 12 months. These patients are separated into two groups depending on whether their cancers progressed to CRPC within 12 months. PCA/SVM could differentiate these two groups with a sensitivity of 85.7% and a specificity of 88.9%. Conclusions: RS has the potential in diagnosis and prognosis of CRPC in clinical practice.
AB - Purpose: We evaluated the feasibility of Raman spectroscopy (RS) in diagnosis and prognosis of castration-resistant prostate cancer (CRPC) in patients with prostate cancer (PC). Materials and methods: Raman spectra are detected from PC cell lines (LNCaP and C4-2) and tissues using a Labram HR 800 RS. Then, principal component analysis (PCA) and support vector machine (SVM) are applied for prediction. A leave-one-out cross-validation is used to train and test the SVM. Results: There are 50 qualified patients, including 33 with androgendependent prostate cancer (ADPC) and 17 with CRPC. The spectral changes at 1126, 1170, 1315 to 1338, and 1447 cm-1 between CRPC and ADPC are detected in both cells and tissues models, which are assigned to specific amino acids and DNA. PCA/SVM algorithm provided a sensitivity of 88.2% and a specificity of 87.9% for diagnosing CRPC tissues. Furthermore, 14 patients with ADPC progressed to CRPC within 12 months. These patients are separated into two groups depending on whether their cancers progressed to CRPC within 12 months. PCA/SVM could differentiate these two groups with a sensitivity of 85.7% and a specificity of 88.9%. Conclusions: RS has the potential in diagnosis and prognosis of CRPC in clinical practice.
KW - Raman spectroscopy
KW - androgen-dependent prostate cancer
KW - castration-resistant prostate cancer
KW - prediction
UR - http://www.scopus.com/inward/record.url?scp=84890094138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890094138&partnerID=8YFLogxK
U2 - 10.1117/1.JBO.18.8.087001
DO - 10.1117/1.JBO.18.8.087001
M3 - Article
C2 - 23907278
AN - SCOPUS:84890094138
SN - 1083-3668
VL - 18
JO - Journal of biomedical optics
JF - Journal of biomedical optics
IS - 8
M1 - 087001
ER -